News and Press

October 14, 2013

BCSI Announces Efforts to Use pH Monitoring to Identify Compromised Platelet Products

DENVER, CO – October 14, 2013 – Blood Cell Storage, Inc. (BCSI), a leading medical device provider based in Seattle, WA announced today during the annual AABB meeting in Denver, Colorado, that they are exploring the viability of using the pH SAFE® products with regular pH readings to identify compromised platelet products.  Laboratory studies are underway whereby multiple daily pH measurements are being collected and where significant changes are being assessed in correlation with bacterial contamination.

This research is important in the effort to help identify and remove bacterially contaminated platelet units from inventory. Older platelets can also be pH monitored to ensure their acceptable performance.

“Since visual signs of contamination are difficult to detect,” said Russ Aldrich, CEO, BCSI. “We believe that using pH measurements to alert for possible bacterial contamination may be an additional way to identify compromised platelet products.”

About BCSI

Blood Cell Storage, Inc. (BCSI) www.bloodcellstorage.com is a privately held international medical device company based in Seattle, Washington, with European operations located in The Netherlands.

BCSI has created two unique product lines that benefit patients, clinicians, researchers, pathologists and doctors using patented technologies. Our fluorescent dyes, micro-fluidics, Nucleic Acid Extraction capabilities and automated systems reduce healthcare costs while improving patient outcomes. www.safesens.com

###

pH SAFE is a registered trademark of BCSI. All other names or product names mentioned in this release are trademarks or registered trademarks of their respective companies.

October 14, 2013

BCSI Announces Americas Launch of SAFE Sens IVM at ASRM; Novel New Approach to Monitor pH in Closed Incubator for In Vitro Fertilization (IVF)

BOSTON, MA – October 14, 2013 – Blood Cell Storage, Inc. (BCSI), a leading medical device provider based in Seattle, WA announced today during the American Society for Reproductive Medicine (ASRM) annual event in Boston, that their newest product, SAFE Sens IVM (in vessel monitoring), has begun shipping to customers and is generally available. SAFE Sens IVM, is a pH monitoring system used by embryologists and clinical staff, that reports, trends and archives pH measurements without disturbing culture conditions within a closed incubator.

About SAFE SensTM

The SAFE Sens (Sterile, Automated Fluoroscopic Evaluation) is an optical fluorescent measurement device. It is used in combination with a disposable sensor, to accurately and reliably measure the pH of small volumes of fluids such as the media used in IVF. The sensor contains a proprietary fluorescent dye that is pH sensitive. Each lot of sterile sensors last six (6) days and have a certification pHID supplied by the manufacturer. This pHID code is used to tell the SAFE Sens device how to specifically interpret the fluorescent measurement for each lot of sensors into a pH value.

Since it is important to make sure that over time the SAFE Sens IVM continues to perform the optical fluorescent measurements properly, the SAFE Sens system uses a Quality Control Standard, qc1. The qc1 device has a known fluorescence value allowing the SAFE Sens device to compare and adjust itself to the known value. When the value is outside of the acceptable bounds the SAFE Sens IVM will alert the user and automatically make an adjustment to bring the system back into control.

“Our early customers are validating that pH monitoring and control is key,” said Russ Aldrich, CEO, BCSI. “We’re hearing over and over that pH control is a requirement for achieving better ART outcomes.”

The SAFE technology is covered by multiple issued and pending US and International equivalent patents. Visit www.safesens.com to learn more about SAFE Sens.

About BCSI

Blood Cell Storage, Inc. (BCSI) www.bloodcellstorage.com is a privately held international medical device company based in Seattle, Washington, with European operations located in The Netherlands.

BCSI has created two unique product lines that benefit patients, clinicians, researchers, pathologists and doctors using patented technologies. Our fluorescent dyes, micro-fluidics, Nucleic Acid Extraction capabilities and automated systems reduce healthcare costs while improving patient outcomes. www.safesens.com

###

SAFE Sens is a trademark of BCSI. All other names or product names mentioned in this release are trademarks or registered trademarks of their respective companies.

July 8, 2013
LONDON, UK – July 08, 2013 – BCSI, a leading medical device provider and Planer PLC, specialists in controlled temperature environments for medical labs and clinics, announced a partnership today during the annual meeting of European Society of Human Reproduction and Embryology (ESHRE). The two companies will collaborate on bringing new technologies to market to address current issues in pH monitoring for Invitro Fertilizaton (IVF) and other uses.

“We are transferring our years of experience in blood storage to other areas where our technology can have a big impact,” said Russ Aldrich, CEO, BCSI. “Because of that experience we are seeing early positive results with this technology in areas such as assisted reproduction.”

“We are excited and proud about the use of our bench-top incubators for assisted reproductive procedures such as IVF,” said Geoffrey Planer, CEO, Planer. “Partnering with BCSI ensures that together we will continue to advance the overall effort for better outcomes for families.”

About Planer

Planer PPC specializes in the control of temperature and other parameters to help customers achieve scientific breakthroughs in biology, medicine and industry. Planer pioneered the development and use of many controlled temperature products as well as monitoring and logging of other key lab parameters. Planer holds a number of patents and has received the Queen’s Award for Technology and awards from the DTI for Innovation and Good Practice in Microelectronics.

###

Planer, and the Planer logo are trademarks of Planer, PLC. BCSI, SAFE Sens and the BCSI logo are trademarks of BCSI. All other names or product names mentioned in this release are trademarks or registered trademarks of their respective companies.

July 8, 2013
LONDON, UK – July 08, 2013 – BCSI, a leading medical device provider and tech²ART, specialists in Assisted Reproduction Technology (ART), announced a partnership today during the annual meeting of European Society of Human Reproduction and Embryology (ESHRE). The two companies will collaborate on bringing new technologies to market to address current issues in pH monitoring for Invitro Fertilizaton (IVF) and other uses.

“Bringing together global experts in ART is an important part of the effort to improve outcomes for clinics and families,” said Russ Aldrich, CEO, BCSI. “The tech²ART team is energetic and focused and we look forward to a successful partnership.”

“BCSI and the SAFE Sens technology they’ve created have an opportunity to make a real impact,” said Michael Similie, General Manager, tech²ART. “Our companies respective strengths are very synergistic and should bring better outcomes faster as we work together to get the technology into clinics.”

About tech²ART

tech²ART Inc. www.tech2art.com is a privately held company that designs, manufactures and markets laboratory equipment primary to the Assisted Reproductive Technology (ART), Embryonic Stem Cell (ESC) and Life Science segment. The rationale for tech²ART is a desire and an ambition to create a strong alternative to current technologies based on a ‘Best in Class’ business model and a customized technology to cover the market needs.

###

tech²ART, and the tech²ART logo are trademarks of tech²ART. BCSI, SAFE Sens and the BCSI logo are trademarks of BCSI. All other names or product names mentioned in this release are trademarks or registered trademarks of their respective companies.

July 8, 2013
LONDON, UK – July 08, 2013 – Blood Cell Storage, Inc. (BCSI), a leading medical device provider based in Seattle, WA and Origio A/S, a leader in delivering innovative Assisted Reproductive Technology solutions headquartered in Måløv Denmark, announced a partnership today during the annual meeting of the European Society of Human Reproduction and Embryology (ESHRE). The two companies will collaborate on bringing new solutions for pH measurement to market to address current issues in monitoring for In Vitro Fertilization (IVF). The first product they will focus on is SAFE Sens IVM, a pH monitoring system used by clinical and research staff, that reports, trends and archives pH measurements without disturbing culture conditions within a closed incubator.

“Embryologists want to monitor pH within media to minimize pH drift and improve their success rates,” said Jesper Funding Andersen, CEO, Origio. “SAFE Sens is easy-to-use, lasts the entire cycle and provides validation to ensure that the system is working properly.”

How SAFE Sens Works

The SAFE Sens (Sterile, Automated Fluoroscopic Evaluation) IVM (In Vessel Monitor) is an optical fluorescent measurement device. It is used in combination with a disposable sensor, to accurately and reliably measuring the pH of small volumes of fluids such as the media used in IVF. The sensor contains a proprietary fluorescent dye that is pH sensitive. Each lot of sterile sensors last 6 days and are pre-calibrated by the manufacturer. An ID code is used to tell the SAFE Sens IVM how to specifically interpret the fluorescent measurement for each lot of sensors into a pH value.

Since it is important to make sure that over time the SAFE Sens IVM continues to perform the optical fluorescent measurements properly, the SAFE Sens IVM has a Quality Control Standard. The SAFE Sens IVM measures the fluorescence and compares it to the known value and reports a number indicating the closeness of the measured and known values. When the value is outside of the acceptable bounds the SAFE Sens IVM will alert the user and automatically make an adjustment to bring the system back into control.

“We are excited to partner with Jesper and his world-class team,” said Russ Aldrich, CEO, BCSI. “SAFE Sens has been adapted from our proven blood storage technology for use specifically in CO2 incubators. Because of this, IVF clinicians now have a highly reliable and significantly lower-priced way to monitor pH”

The SAFE technology is covered by multiple issued and pending US and International equivalent patents. Visit www.origio.com to learn more about SAFE Sens.

About Origio

ORIGIO a/s is a world leader in delivering innovative Assisted Reproductive Technology (ART) solutions that enhance the work of ART to the benefit of families. ORIGIO is headquartered in Måløv, Denmark.

With 6 production facilities, 13 subsidiaries and many more distributors, ORIGIO has a strong presence worldwide with a broad product portfolio for the ART market and is highly reputed among opinion leaders and customers.

In June 2012, The Cooper Companies, Inc. operated through the business unit CooperSurgical acquired ORIGIO. CooperSurgical, a leader in women’s healthcare products, shares the vision of delivering life-changing products to health care professionals. Cooper Companies is listed on the New York Stock Exchange. www.origio.com

###

SAFE Sens is a trademark of BCSI. All other names or product names mentioned in this release are trademarks or registered trademarks of their respective companies.

June 24, 2013
BCSI will be attending the ESHRE event in London, England from July 8- July 11, 2013. Contact us if you plan on being there, too.

August 16, 2012
New Monitoring Device to Increase the Safety of Blood Transfusions

The US Army Medical Research and Material Command, Telemedicine & Advance Technology Research Center Highlights their involvement with the pH SAFE technology as a way to increase the safety of blood transfusions. Read the full article here (pdf).

May 24, 2011
Sanquin, the blood supply repository and authority for the Netherlands, announced completion of a 15,000 platelet bag evaluation on March 28, 2011 with the data analysis of the Blood Cell Storage, Inc. (BCSI) pH1000 system; a non-invasive pH level detection system using a fluorescent sensor and automated reader. As a result of this study they have now released a request for bids on new platelet collection sets. As an option on those sets they desire the inclusion of the BCSI pH system. BCSI is pleased to be currently working with platelet bag suppliers to integrate our non-invasive pH sensors into their offerings for Sanquin's platelet collection sets.

January 1, 2010
BCSI Wins Fiscal Year 2010 Department of Defense Appropriation

BCSI has been approved to receive a $1.6M U.S. Fiscal Year 2010 Defense Appropriation as included in the Department of Defense appropriations bill submitted by U.S. Senator Patty Murray, approved by both houses and signed by the President. Senator Murray indicated that, “This funding would help the Army develop a capability to ensure the efficacy of platelets in large samples. Platelets are necessary to stop blood loss from severe injuries. This project would help reduce battlefield deaths caused by transfusions of ineffective platelets.”

The DOD appropriation recognizes the importance of rapid, user friendly measurement of pH to assure the quality of platelets for transfusions utilizing BCSI proprietary technology.

June 1, 2009
Amsterdam, Sanquin Blood Bank North East in the Netherlands, implemented 100% pH measurement for all of its produced buffy coat platelets, utilizing the BCSI pH1000 System and system at the blood bank after processing, at the distribution centres and at all the major hospitals in the North Eastern part of the Netherlands.

After a year Sanquin will evaluate the data, system and the BCSI platelet storage bags to determine if the platelet storage time can be increased in the Netherlands. This is a major achievement for BCSI, as the leadership of Sanquin throughout the EU is expected to have a positive cascading effect in other countries.

Sanquin Blood Bank is non-invasively measuring pH with the BCSI pH1000 System.

January 2008
Quality of Platelets can be measured fast and efficient by new invention

May 2007
BCSI receives CE Mark Approval for novel platelet storage bag technology

March 31, 2006
BCSI certified ISO 13485:2003.

March 14, 2006
"Big idea, small machine" - New testing machine could keep platelets safely sterile longer article in the King County Journal by Clayton Park.

January 16, 2006
"Small, ambitious biotech bags $3.6M" - Article in the Puget Sound Business Journal by Eric Engleman.

October 17, 2005
New Study Demonstrates Accuracy of Non-Invasive Method to Measure Platelet pH; Blood Cell Storage, Inc., (BCSI) today released preliminary results showing its proprietary pH Monitoring System can determine the pH of platelets while maintaining bag sterility. The results were presented today at the Annual Meeting of the American Association of Blood Banks (AABB) in Seattle, Washington.
Learn more

March 4, 2005
Platelet rich plasma product verification. BCSI has successfully measured the pH in multiple platelet and plasma samples using our prototype instrument with various interfering substances. These studies were carried out in collaboration with our partners at Sanquin.

January 17, 2005
pH detector manufacturing prototype instruments and inserts completed. BCSI announces that the manufacturing prototype pH readers have been completed. These machines will perform our optical pH measurement of the plasma bag contents. BCSI has also completed the design and mold building for our injection molded blood bag inserts. These inserts will house the surface for our optical pH sensitive chemistry.